$VTRS

Viatris (VTRS) reported Q2 2026 with higher sales and revenue, completed a $1.15B share buyback, and raised 2026 revenue guidance to $14.75B, despite a net loss. The company affirmed a $0.12 quarterly dividend. Management's confidence is noted, but pricing pressure and regulatory risks remain concerns.

Simply Wall St reports Viatris (VTRS) raised its 2026 earnings guidance with Q2 results showing higher year-on-year sales and revenue and a return to net profitability in the first half. The stock at $16.23 is described as about 12.3% below a $18.50 fair value estimate, with risks including generic price competition and regulatory scrutiny.

A peer comparison of Q2 results in generic pharmaceuticals says the four tracked companies beat analysts’ revenue consensus by 2.6% on average, but shares fell 5.6% since reporting. ANI Pharmaceuticals (ANIP) revenue was $266m (+25.9%), EPS beat, but full-year revenue guidance missed; stock down 9.1% to $75.12. Amphastar (AMPH) revenue $183.9m (+5.4%) beat; stock up 2.3% to $20.28. Viatris (VTRS) revenue $3.76b (+4.9%) beat; stock down 7.6% to $16.32. Amneal (AMRX) revenue $796.2m (+9.9%) beat;

Viatris (VTRS) reported Q2 2026 revenue of $3.8B, up 3.5% operationally, with adjusted EBITDA of $1.2B and adjusted EPS of $0.69. Management raised 2026 guidance for revenue ($14.55B-$14.95B), adjusted EBITDA ($4.3B-$4.5B) and adjusted EPS ($2.45-$2.59). It also cited Nashik supply disruptions and FDA approval for its Gwyn Lo patch.

Theravance Biopharma reported Q2 2026 revenue of $20.7M, all from its Viatris collaboration, up 11% YoY. GAAP net loss was $5.9M. Cash and marketable securities were $387.7M at June 30, 2026. The company said a Zymeworks acquisition is expected to close in H2 2026, and it cited restructuring cost savings.

Viatris (VTRS) shares fell about 6.4% after the company reported higher Q2 and year-to-date revenues, returned to net income for six months, and raised 2026 revenue guidance midpoint to $14.75B. Viatris completed a $1.15B buyback (8.7% of shares), affirmed a $0.12 quarterly dividend, and cited FDA approval of its Gwyn Lo contraceptive patch.

Simply Wall St says Viatris (VTRS) shares have gained 76.1% over 12 months but still trade at a discount on price-to-sales. It cites a P/S near 1.3x versus pharma industry ~5.0x and a fair P/S model around 3.5x. It also notes FDA approval for the once-weekly Gwyn Lo patch and a planned sale of TYRVAYA rights to Harrow.

Viatris (NASDAQ:VTRS) reported Q2 CY2026 revenue of $3.76 billion, up 4.9% year on year, and non-GAAP EPS of $0.69, 15% above consensus, according to the company. Full-year revenue guidance is about $14.75 billion. Management cited Greater China growth and pipeline progress, but noted supply and China policy risks.

Viatris reported Q2 2026 results on Aug. 6, with total revenue of $3.76B, up 5% YoY, and adjusted EBITDA of $1.2B, up 8% operationally. It posted a U.S. GAAP net loss of $119M. The company cited strong Greater China performance, U.S. FDA approval of Gwyn Lo, Tyrvaya rights sale, raised 2026 guidance midpoints, returned about $550M to shareholders, and cut gross leverage to 2.9x.

Viatris (VTRS) shares fell about 7.7% as investors weighed execution and supply-disruption risks despite improved outlook. The company reported Q2 2026 revenue of about $3.8B (+5%) and adjusted EPS of $0.69, and raised 2026 guidance. It warned second-half revenue could be reduced by $100M to $150M due to Nashik remediation and FDA Form 483 issues, plus a GAAP net loss of about $119M tied largely to a planned Tyrvaya rights sale.